A tighter archive for life-science signals.
Search once, then narrow by source or topic.
Radiopharmaceutical specialist Aktis seeks an IPO
Radiopharmaceutical specialist Aktis seeks an IPO
Cytokinetics set to battle Bristol Myers as FDA approves heart drug
Cytokinetics set to battle Bristol Myers as FDA approves heart drug
Patient deaths put Merck, Daiichi’s ADC trial on partial hold
Patient deaths put Merck, Daiichi’s ADC trial on partial hold
BioMarin to buy rare disease drugmaker Amicus for $4.8B
BioMarin to buy rare disease drugmaker Amicus for $4.8B
Novo files for CagriSema approval; Merck and Pfizer’s trial win
Novo files for CagriSema approval; Merck and Pfizer’s trial win
Galapagos TYK2 drug hits goal in one trial, misses in another
Galapagos TYK2 drug hits goal in one trial, misses in another
Moderna gets funding for H5 pandemic influenza vaccine
Moderna gets funding for H5 pandemic influenza vaccine
Lilly obesity pill, headed for quick FDA review, hits mark in ‘maintenance’ trial
Lilly obesity pill, headed for quick FDA review, hits mark in ‘maintenance’ trial
Insmed’s ‘win streak’ ends as top drug fails study in chronic nasal condition
Insmed’s ‘win streak’ ends as top drug fails study in chronic nasal condition
Takeda says $4B TYK2 drug succeeds in large psoriasis studies
Takeda says $4B TYK2 drug succeeds in large psoriasis studies
Orum, a biotech marrying ADCs with protein degraders, captures $100M in funding
Orum, a biotech marrying ADCs with protein degraders, captures $100M in funding
FDA clears GSK’s twice-yearly asthma drug
FDA clears GSK’s twice-yearly asthma drug
Peanut allergy patch succeeds in late-stage study 5 years after FDA rejection
Peanut allergy patch succeeds in late-stage study 5 years after FDA rejection
RA Capital backs drug for rare kind of chronic pain
RA Capital backs drug for rare kind of chronic pain
Addition emerges with $100M to make gene therapies for chronic and rare diseases
Addition emerges with $100M to make gene therapies for chronic and rare diseases
Developing a path forward in cancer cachexia
Developing a path forward in cancer cachexia
Nektar sees silver lining as autoimmune drug ‘narrowly’ misses in alopecia study
Nektar sees silver lining as autoimmune drug ‘narrowly’ misses in alopecia study
FDA ‘proactively’ hands J&J a voucher; Pfizer issues 2026 forecasts
FDA ‘proactively’ hands J&J a voucher; Pfizer issues 2026 forecasts
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page